TLDR
- UNH Q1 EPS came in at $7.23, beating the $6.59 consensus by ~9.7%; revenue of $111.7B topped estimates
- Full-year 2026 adjusted EPS guidance raised to above $18.25, up from above $17.75
- Medical benefit ratio improved to 83.9%, better than the 85.5% analysts expected
- JPMorgan raised its price target to $420; Erste Group upgraded to Buy
- UNH is outperforming the broader market, up ~3.6% while the S&P 500 is down 0.64%
UnitedHealth Group (UNH) is having a strong session on Tuesday, gaining around 3.6% while the broader market trades lower. The S&P 500 is down 0.64% and the Nasdaq is off 1.17%, making UNH’s move entirely stock-specific.
UnitedHealth Group Incorporated, UNH
The rally comes off the back of a Q1 2026 earnings report that beat on both the top and bottom line. Adjusted EPS came in at $7.23 against a consensus of $6.59 — a beat of roughly 9.7%. Revenue hit $111.7 billion, ahead of the $109.44 billion estimate.
UNH also raised its full-year 2026 adjusted EPS guidance to above $18.25 per share, up from the prior outlook of above $17.75.
Cost Control Catches Analysts’ Attention
One number stood out beyond the headline figures. UNH’s medical benefit ratio — the percentage of premiums paid out in claims — came in at 83.9% for the quarter. Analysts had forecast 85.5%. A lower ratio means the company is spending less on claims relative to premiums collected, which is good for margins.
That compares to 84.8% in the same quarter last year, showing year-over-year improvement.
CEO Stephen Hemsley said the company is “continuing to help simplify and modernize health care,” citing value, affordability, and transparency as priorities.
Wall Street responded. JPMorgan raised its price target on UNH to $420 from $389. Erste Group upgraded the stock to Buy from Hold. Leerink Partners lifted its target to $400 and maintained an outperform rating. Morgan Stanley moved its target to $395 with an overweight rating.
The consensus rating across analysts tracked by MarketBeat sits at “Moderate Buy,” with an average target price of $377.64.
Policy Backdrop and Institutional Activity
The earnings beat lands just weeks after the Trump administration finalized a larger-than-expected 2027 payment rate increase for Medicare Advantage plans — a direct positive for UNH’s business.
On the institutional side, Wealthfront Advisers raised its UNH stake by 6.2% in Q4, adding 5,637 units to hold 96,224 worth roughly $31.77 million. A number of other firms also added to positions in recent quarters. Institutional investors now own 87.86% of the stock.
UNH also announced a $2 billion share buyback program, which it expects to complete by the end of Q2 2026.
There are a few notes of caution. CEO Patrick Conway sold 800 units at around $355 on April 23, a 4.30% reduction in his personal holding. Some analysts have flagged near-term valuation risk after the stock’s run, with one Seeking Alpha piece arguing the rally moved “too far, too fast.”
The stock’s 52-week range runs from $234.60 to $424.12. It currently trades with a P/E of 26.79 and a market cap of around $322 billion.
UNH pays a quarterly dividend of $2.21 per unit, representing an annualized yield of approximately 2.5%.
🚨 Our April Stock Picks Are Live!
A new month means new opportunities. Our analysts have just released their top stock picks for April, highlighting companies with strong momentum that rank highly on our KO Score algorithm. We’re also now sharing trade ideas for both long-term and short-term investors, giving you more ways to spot potential opportunities in the market.
Sign up to Knockout Stocks today and get 50% off to unlock the full list and see which stocks made the cut.
Use coupon code Special50 for your exclusive discount!
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
